If 75 percent of the obese patients with type 2 diabetes achieved remission after gastric bypass surgery, would you say it sounds too good to be true?
A recent study published in the Diabetologia journal from the European Association for the Study of Diabetes reports that the obesity surgery known as Roux-en-Y (RYGB) is helping patients with diabetes shed weight and their type 2 diabetes diagnosis.
The study focused on the effects of RYGB on diabetes remission, predicting factors, likelihood of relapse, surgical complications, and incidence of microvascular (retinopathy, neuropathy, etc.) and macrovascular (clogged arteries) complications.
The claim of diabetes remission, however, gives some diabetes health practitioners cause for concern.
The Roux-en-Y gastric bypass is one of many weight-loss surgery options available today. It consists of two components, explains the American Society for Metabolic and Bariatric Surgery (ASMBS).
The surgery reduces the size of the stomach by dividing the top of the stomach from the rest of the stomach. The first section of the small intestines is also divided and essentially shortened, then reconnected to the smaller pouch of the stomach.
The result is that patients become limited in how many calories they can consume in one sitting and over the source of the day. Overeating results in pain, vomiting, and a significant degree of discomfort.
Patients also lose weight because the entire digestive system is now absorbing fewer calories — which means fewer vitamins and minerals, too.
The ASMBS adds, “Most importantly, the rerouting of the food stream produces changes in gut hormones that promote satiety, suppress hunger, and reverse one of the primary mechanisms by which obesity induces type 2 diabetes.”